Sign In
Buy RVVTF
$0.0190
+0.0010 (+5.56%)
At Close: Jul 31, 2026
Revive Therapeutics says arranging private placement of up to $5M of units at a price of 15 cents each
06:44am, Thursday, 01'st Dec 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has said it is arranging a private placement of a minimum of $3 million and up to $5 million of units at a price of 15 cents per unit, with the offering�
Revive Therapeutics on target in FDA submission for study of COVID-19 drug, say Leede Jones Gable analysts
11:23am, Friday, 25'th Nov 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has made a key protocol amendment for its COVID-19 drug trial and in its plans to submit a Type C meeting request with the Federal Drug Administration (F
Revive Therapeutics finalizes amended Phase 3 COVID-19 study protocol for FDA submission
02:59pm, Friday, 14'th Oct 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that it has finalized an amended protocol to the US Food & Drug Administration (FDA) for the company's Phase 3 clinical trial (NCT04504734) to
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) told investors that results from a Phase I/II clinical study of oral psilocybin to treat complications faced by adults using the addictive drug methamphe
Revive Therapeutics files amended protocol for Bucillamine trial with US FDA
07:43am, Wednesday, 14'th Sep 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has filed an amended protocol to the US Food & Drug Administration (FDA) for the company's Phase 3 clinical trial to evaluate the safety and effi
Revive Therapeutics to amend study protocol for Bucillamine trial for resubmission to US FDA
08:35am, Tuesday, 16'th Aug 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it will amend the study protocol for the Phase 3 clinical trial evaluating the safety and efficacy of Bucillamine in patients with mild to moderate
The Growth Potential Of Psychedelics Stocks And ETFs
01:54pm, Thursday, 28'th Jul 2022
On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan
Revive Therapeutics provides update on proposed amended study protocol for its Phase 3 bucillamine for COVID-19 clinical trial
11:29am, Monday, 25'th Jul 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has provided investors with an update on its US Food and Drug Administration (FDA) Phase 3 clinical trial evaluating the safety and efficacy of bucillami
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has announced that the US Food & Drug Administration (FDA) accepted the company's Data Access Plan (DAP) submission for a Phase 3 trial of Bucillamine in
Revive Therapeutics submits data access plan for Bucillamine in coronavirus clinical trial to FDA
02:43pm, Monday, 06'th Jun 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has updated further on its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19), saying it has now submitted a Data Access Plan to the US Fo
Revive Therapeutics to advance its drug pipeline for inflammatory liver disorders amid growing cases of acute hepatitis in children
08:43am, Tuesday, 31'st May 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has announced plans to advance its drug pipeline for inflammatory liver disorders in light of the growing number of cases of acute hepatitis in children
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has received positive comments from the Food and Drug Administration (FDA) regarding the company's request to determine and agree on new primary
Revive Therapeutics submits request to FDA for potential new endpoints for Bucillamine clinical trial to treat COVID-19
12:40pm, Monday, 16'th May 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that it has submitted a request to the US Food & Drug Administration (FDA) to determine and agree on the potential new primary efficacy endpoi
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has been in discussions with the Biomedical Advanced Research and Development Authority (BARDA) to explore the potential of securing advanced dev
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
02:26pm, Monday, 18'th Apr 2022 InvestorsHub
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact...
